Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
Phase 1
8
about 3.7 years
45–80
1 site in MA
What this study is about
This trial is testing the safety and tolerability of surgically transplanting cells derived from your own skin stem cells into the brain to help treat Parkinson's disease. The transplanted cells will be dopaminergic, meaning they produce dopamine, a chemical that helps control movement.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive autologous dopaminergic cell implantation
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Safety and Tolerability
Secondary: Change in PD medication usage, Change in Parkinson's disease related quality of life, Global impression of change
Neurology